Andrew J. Cooper, MSc

Articles by Andrew J. Cooper, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

ByDavid T. Liss, PhD,Manisha Cherupally, MS,Matthew J. O’Brien, MD, MSc,Raymond H. Kang, MA,Cassandra Aikman, MPH,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Eleena Koep, MS,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

December 12th 2023

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

ByDavid T. Liss, PhD,Raymond H. Kang, MA,Nicola Lancki, MPH,Matthew J. O’Brien, MD, MSc,Amisha Wallia, MD, MS,Andrew J. Cooper, MSc,Sterling A. Harris, BA,Emily D. Parker, PhD, MPH,Ronald T. Ackermann, MD, MPH

March 9th 2021

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

Latest Updated Articles

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications
March 9th 2021
Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes
December 12th 2023

Andrew J. Cooper, MSc

Articles by Andrew J. Cooper, MSc

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

Latest Updated Articles

Trending on AJMC

Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently

Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

5 Ongoing Clinical Trials in Myeloproliferative Neoplasms

Defunding Co-Payment Assistance Disrupted nAMD Care